Polypeptide Attached To Or Complexed With The Agent (e.g., Protein, Antibody, Etc.) Patents (Class 424/9.34)
  • Patent number: 11333669
    Abstract: The invention provides mass spectrometry methods, compositions and systems which enable a unique platform for analyte quantitation accessing very high degrees of multiplexing and accurate quantification, particularly well-suited for a range of quantitative analysis for proteomics applications. Embodiments of the present methods and systems combine isotopic coding agents characterized by very small differences in molecular mass with mass spectrometry methods providing large resolving power to provide relative or absolute analyte quantification in a large number of samples.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: May 17, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Joshua J. Coon, Alex Hebert
  • Patent number: 11318206
    Abstract: A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 3, 2022
    Assignee: APOSENSE LTD
    Inventor: Ilan Ziv
  • Patent number: 11305023
    Abstract: An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: April 19, 2022
    Inventor: Sam Popinchalk
  • Patent number: 11191771
    Abstract: This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 7, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Travis Biechele, Rory Rohm, Robert Thurman
  • Patent number: 11119099
    Abstract: A method of making a nanocomposite includes forming at least one gold nanorod; coating a silver layer on an outer surface of the gold nanorod; assembling a Raman reporter molecule layer on the coated silver layer; coating a pegylated layer on the assembled Raman reporter molecule layer; and conjugating the coated pegylated layer with an active layer, the active layer comprising at least one of a targeting molecule configured to bind to the target of interest and a functional molecule configured to interact with the target of interest.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: September 14, 2021
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Alexandru S. Biris, Andrew G. Kumpuris, Zeid Nima
  • Patent number: 11097019
    Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: August 24, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Daniel Heller, Januka Budhathoki-Uprety
  • Patent number: 11077215
    Abstract: The invention provides an improved modified magnetosome that contains more iron therein with the combination of the expressed genes. This is achieved by co-expression of (a) one or more bacterial magnetotactic genes to amplify iron uptake, compartmentalization and biomineralization in cells, with (b) one or more mammalian iron handling proteins that together augment(s) and/or regulate the cells iron pool. As a result, mammalian cells or bacterial cells that are transfected or transformed, respectively, can be more effectively tracked using various imaging technologies.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: August 3, 2021
    Assignee: Multi-Magnetics Incorporated
    Inventors: Donna E. Goldhawk, D. James Koropatnick, Rene Figueredo, Frank S. Prato, R. Terry Thompson, Neil Gelman
  • Patent number: 11040222
    Abstract: Edema in tissue of a patient undergoing a course of radiation therapy or treatment can be estimated based on one or more MRI measurements used to measure changes in fluid content of various tissues. A correlation between observed changes in edema and one or more delivered fractions of radiation can be used to drive one or more clinical actions. Methods, systems, articles of manufacture, and the like are described.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: June 22, 2021
    Assignee: VIEWRAY TECHNOLOGIES, INC.
    Inventor: James F. Dempsey
  • Patent number: 11034767
    Abstract: Provided herein, in some embodiments, are antibodies, antigen-binding antibody fragments, chimeric antigen receptors (CARs) and bispecific T cell engagers (BiTEs) that bind specifically to B7 homolog 6. Also provided herein are methods of using the same and cells comprising the same.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 15, 2021
    Assignee: Trustees of Dartmouth College
    Inventors: Margaret Ackerman, Casey Hua, Charles Sentman
  • Patent number: 10955504
    Abstract: Some aspects include a method of detecting change in biological subject matter of a patient positioned within a low-field magnetic resonance imaging device, the method comprising: while the patient remains positioned within the low-field magnetic resonance device: acquiring first magnetic resonance image data of a portion of the patient; acquiring second magnetic resonance image data of the portion of the patient subsequent to acquiring the first magnetic resonance image data; aligning the first magnetic resonance image data and the second magnetic resonance image data; and comparing the aligned first magnetic resonance image data and second magnetic resonance image data to detect at least one change in the biological subject matter of the portion of the patient.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 23, 2021
    Assignee: Hyperfine Research, Inc.
    Inventors: Michal Sofka, Jonathan M. Rothberg, Gregory L. Charvat, Tyler S. Ralston
  • Patent number: 10947350
    Abstract: Provided are multiply functional charged telodendrimers. The telodendrimers can be used for protein encapsulation and delivery. The charged telodendrimers may have one or more crosslinking groups (e.g., boronic acid/catechol reversible crosslinking groups). The telodendrimers can aggregate to form nanoparticles. Cargo such as combinations of proteins and other materials may be sequestered in the core of the nanoparticles via non-covalent or covalent interactions with the telodendrimers. Such nanoparticles may be used in protein delivery applications.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: March 16, 2021
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Juntao Luo, Xu Wang, Changying Shi
  • Patent number: 10942163
    Abstract: Devices for micro-fluid mixing micro-fluids are presented, together with example methods for micro-mixing using example devices. An example device may include a micro-volume fluid chamber (?VFC), a micro-volume mixing chamber (?VMC), and a source of a target micro fluid. The ?VFC may include two slidably-mounted piston segments that divide the ?VFC into three sub-volumes, one of which initially contains a mixer micro-fluid. The source of the target micro fluid may be triggered to deliver the target micro-fluid into another of the sub-volumes via an inlet channel. A propellant may be triggered to drive axial motion of the piston segments, causing the sub-volumes to compress. Through this action, the mixer micro-fluid may be expelled via a first outlet channel into the ?VMC, and the target micro-fluid may be expelled via a second outlet channel into the ?VMC. As the piston segments move, they block and unblock the inlet and outlet channels.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 9, 2021
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Benjamin David Krasnow, Eric Peeters, Peter Howard Smith, Ethan Glassman
  • Patent number: 10899741
    Abstract: The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-? inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-? overexpression. The substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Guangyuan Shen, Feng He, Weikang Tao
  • Patent number: 10849974
    Abstract: Optogenetic and chemogenetic actuators are critical for deconstructing the neural correlates of behavior. However, these tools have several drawbacks, including invasive modes of stimulation or slow on/off kinetics. These disadvantages have been overcome by synthesizing a magnetically sensitive actuator, Magneto, comprised of the cation channel, TRPV4, fused to the paramagnetic protein, ferritin. Magneto permits non-invasive magnetic control over neuronal activity by showing remote stimulation of cells using in vitro calcium imaging assays, electrophysiological recordings in brain slices, in vivo electrophysiological recordings in freely moving mice, and behavioral outputs in zebrafish and mice. As proof of concept, the first magnetogenetic control of the nervous system was demonstrated by using Magneto to delineate a causal role of striatal dopamine receptor 1 neurons in mediating reward behavior in mice.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 1, 2020
    Assignee: University of Virginia Patent Foundation
    Inventors: Ali Deniz Guler, Michael Alex Wheeler
  • Patent number: 10835763
    Abstract: Edema in tissue of a patient undergoing a course of radiation therapy or treatment can be estimated based on one or more MRI measurements used to measure changes in fluid content of various tissues. A correlation between observed changes in edema and one or more delivered fractions of radiation can be used to drive one or more clinical actions. Methods, systems, articles of manufacture, and the like are described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 17, 2020
    Assignee: VIEWRAY TECHNOLOGIES, INC.
    Inventor: James F. Dempsey
  • Patent number: 10821303
    Abstract: Edema in tissue of a patient undergoing a course of radiation therapy or treatment can be estimated based on one or more MRI measurements used to measure changes in fluid content of various tissues. A correlation between observed changes in edema and one or more delivered fractions of radiation can be used to drive one or more clinical actions. Methods, systems, articles of manufacture, and the like are described.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: November 3, 2020
    Assignee: VIEWRAY TECHNOLOGIES, INC.
    Inventor: James F. Dempsey
  • Patent number: 10814020
    Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: October 27, 2020
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Mani Salarian, Shanshan Tan
  • Patent number: 10751423
    Abstract: Disclosed are methods of treating cancer of the intraperitoneal cavity using compositions comprising nanoparticles without targeting agents. In addition, nanoparticles are described that comprise a highly toxic anticancer agent (e.g., an anticancer agent having an IC50 less than 1 nM) covalently bound via a linker to a triblock copolymer. Other nanoparticles that comprise Pt(IV) and an anticancer agent are also described. Also disclosed are nanoparticles comprising imaging agents non-covalently associated with a polymer, and methods of imaging cancer of the intraperitoneal cavity using compositions comprising nanoparticles without targeting agents.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: August 25, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Paiman Peter Ghoroghchian, Ruogu Qi, Angela M. Belcher, Xiangnan Dang, Zhimin Tao
  • Patent number: 10675364
    Abstract: The present disclosure encompasses embodiments of a novel near-infrared-emitting molecular fluorophore and probes incorporating said fluorophore advantageous for in vitro and in vivo research studies. The fluorophore is robust, photostable, and possesses functionalities for easy bioorthogonal conjugation (e.g., click chemistry, hydrazone formation, Diels Alder, Staudinger ligation, etc.). It is biocompatible and emits at 711 nm in aqueous conditions. These fluorophores may be used to fluorescently tag biological molecules or structures of interest, or used as optical reporters (i.e., activatable molecular probes, fluorescent dyes) for specific biomarkers/analytes as they can be switched from “off” to “on.” This fluorophore is useful for cellular assays and preclinical small animal imaging as the near-infrared emission is highly penetrating, and the photophysical properties are outstanding. As such, the properties of this class of fluorophores could easily be translated for use in clinical applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 9, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Kenneth Hettie, Jessica Klockow, Timothy Glass, Frederick T. Chin
  • Patent number: 10618819
    Abstract: The patent relates to para amino benzoic acid (pABA) sensitized terbium (Tb3+) doped spherical LaF3 nanoparticles used for detection of nitro group containing compounds using the terbium (Tb3+) doped spherical LaF3 nanoparticles sensitized by para amino benzoic acid (pABA).
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 14, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Meitram Niraj Luwang, Debasish Ghosh
  • Patent number: 10590394
    Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 17, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Daniel Popkin
  • Patent number: 10585156
    Abstract: Some aspects include a method of detecting change in degree of midline shift in a brain of a patient. The method comprises, while the patient remains positioned within the low-field magnetic resonance imaging device, acquiring first magnetic resonance (MR) image data and second MR image data of the patient's brain; providing the first and second MR data as input to a trained statistical classifier to obtain corresponding first and second output, identifying, from the first output, at least one initial location of at least one landmark associated with at least one midline structure of the patient's brain; identifying, from the second output, at least one updated location of the at least one landmark; and determining a degree of change in the midline shift using the at least one initial location of the at least one landmark and the at least one updated location of the at least one landmark.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 10, 2020
    Assignee: Hyperfine Research, Inc.
    Inventors: Michal Sofka, Jonathan M. Rothberg, Gregory L. Charvat, Tyler S. Ralston
  • Patent number: 10568976
    Abstract: A compound of the following general formula (I), and isomers, physiologically acceptable salts, and complexes thereof, for use as a contrast agent in diagnostic imaging:
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: February 25, 2020
    Assignee: DEBRECENI EGYETEM
    Inventors: Richárd Botár, Zoltán Garda, Tamás Fodor, Ferenc Krisztián Kálmán, Viktória Nagy, Gyula Tircsó, Imre Tóth
  • Patent number: 10416264
    Abstract: Some aspects include a method of detecting change in degree of midline shift in a brain of a patient. The method comprises, while the patient remains positioned within the low-field magnetic resonance imaging device, acquiring first magnetic resonance (MR) image data and second MR image data of the patient's brain; providing the first and second MR data as input to a trained statistical classifier to obtain corresponding first and second output, identifying, from the first output, at least one initial location of at least one landmark associated with at least one midline structure of the patient's brain; identifying, from the second output, at least one updated location of the at least one landmark; and determining a degree of change in the midline shift using the at least one initial location of the at least one landmark and the at least one updated location of the at least one landmark.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: September 17, 2019
    Assignee: Hyperfine Research, Inc.
    Inventors: Michal Sofka, Jonathan M. Rothberg, Gregory L. Charvat, Tyler S. Ralston
  • Patent number: 10300307
    Abstract: A focused ultrasound (“FUS”} system capable of use in a small bore imaging system, such as a small bore magnetic resonance imaging (“MRI”} system is provided. The FUS system generally includes an ultrasound transducer whose position is adjusted by a positioning system. The positioning system is sized to fit within the bore of the small bore imaging system. For instance, the positioning system can fit within a diameter of 150 millimeters or less.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: May 28, 2019
    Assignee: Sunnybrook Research Institute
    Inventors: Kullervo Hynynen, Anthony Chau, Rajiv Chopra
  • Patent number: 10300011
    Abstract: Methods and devices for three-dimensional navigation of magnetic nanoparticles are provided. A method can comprise introducing high-anisotropy magnetic nanoparticles to a mammal and directing the high-anisotropy magnetic nanoparticles towards a target region of the mammal. Direction control is achieved by subjecting the high-anisotropy magnetic nanoparticles to an alternating signal comprising a uniform magnetic field pulse having a strength greater than a coercivity of the high-anisotropy magnetic nanoparticles and a magnetic gradient pulse having a highest strength that is less than the coercivity of the high-anisotropy magnetic nanoparticles and a location of a lowest strength at the target region of the mammal, and the direction of the uniform magnetic field pulse being in an opposite direction of the magnetic gradient pulse.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 28, 2019
    Assignee: The Florida International University Board of Trustees
    Inventors: Sakhrat Khizroev, Tiffanie Stewart, Abhignyan Nagesetti
  • Patent number: 10232062
    Abstract: The invention relates to a radiolabelled material comprising a polymer, a radioactive isotope, and an immobilizing agent, wherein the immobilizing agent is capable of immobilizing the radioactive isotope on or in the polymer, and wherein the immobilizing agent is a macromolecule comprising electron donating groups. The invention also relates to a process for making a radiolabelled material, to use of a radiolabelled material for the preparation of medicaments for treating cancer and/or for radiation imaging, and to use of a radiolabelled material in the treatment of cancer. There is further described use of an immobilizing agent to immobilize a radioactive isotope on or in a polymer.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 19, 2019
    Assignee: The Australian National University
    Inventors: Ross Wentworth Stephens, Jessica Louise Bell
  • Patent number: 10232060
    Abstract: The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable stereoisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable stereoisomers in solution useful as concentration independent CEST responsive agents.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: March 19, 2019
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Silvio Aime, Daniela Delli Castelli, Franco Fedeli, Dario Livio Longo, Enzo Terreno, Fulvio Uggeri
  • Patent number: 10131693
    Abstract: The present invention deals with a bipodal-peptide binder that specifically binds with a target including (a) a structure stabilizing region that includes parallel, antiparallel or parallel and antiparallel amino acid strands wherein interstrand non-covalent bonds are formed; and (b) a target binding region I and a target binding region II that are bonded at both terminals of said structure stabilizing region and respectively include n and m amino acids, and a method of preparing same; the bipodal-peptide binder of the present invention exhibits the KD value (dissociation constant) of a very low level (for example, nM level) and, therefore, exhibits very high affinity toward a target. The bipodal-peptide binder of the present invention has applications not only in pharmaceuticals but also in in-vivo imaging, in vitro cell imaging, and drug delivery targeting, and can be very usefully employed as an escort molecule.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: November 20, 2018
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sang Yong Jon, Sung Hyun Kim, Se Ho Park
  • Patent number: 10117912
    Abstract: The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: November 6, 2018
    Assignee: Regents of the University of Minnesota
    Inventors: Ronald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor
  • Patent number: 9814790
    Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged.
    Type: Grant
    Filed: May 13, 2017
    Date of Patent: November 14, 2017
    Assignee: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey Bazarov
  • Patent number: 9801906
    Abstract: A colloid or crystalline solution with the addition of poly-oxygenated metal hydroxide particles. The solution is configured to treat a condition of a mammal, including a human individual and an animal including a depletion of hemoglobin and hemorrhagic shock. The solution can be intravenously administered. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 31, 2017
    Inventors: Erica D. Bruce, Christie Sayes, John W. Woodmansee, Jr.
  • Patent number: 9752129
    Abstract: The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell. The secreted polypeptide can be a selectable marker, a reporter protein, a transcription factor, a signal pathway protein, a receptor, a growth factor, a cytokine, an effector molecule or other factors that can produce a phenotype in the host cell.
    Type: Grant
    Filed: October 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey Bazarov, Abdul Wakeel, Joyce Barrozo
  • Patent number: 9682103
    Abstract: A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly -oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: June 20, 2017
    Assignee: Baylor University
    Inventors: Erica D. Bruce, Christie Sayes, John W. Woodmansee, Jr.
  • Patent number: 9676855
    Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: June 13, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
  • Patent number: 9649335
    Abstract: A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly-oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: May 16, 2017
    Assignee: Baylor University
    Inventors: Erica D. Bruce, Christie Sayes, John W. Woodmansee, Jr.
  • Patent number: 9585841
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 7, 2017
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Patent number: 9555131
    Abstract: An imaging agent for detecting analytes in an environment includes functionalized nanodiamonds and functionalized magnetic particles that can selectively interact with an analyte. Each functionalized nanodiamond contains at least one color center configured emit light in response to illumination. At least one property of the light emitted by the color centers is related to the proximity of the functionalized magnetic particles to the color centers. This property can be detected to determine that the functionalized nanodiamonds are proximate to the functionalized magnetic particles, to determine that the functionalized nanodiamonds and the functionalized magnetic particles are interacting with the analyte, or other applications. Devices and methods for detecting properties of the analyte by interacting with the functionalized nanodiamonds and functionalized magnetic particles are also provided.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: January 31, 2017
    Assignee: Verily Life Sciences LLC
    Inventors: Victor Marcel Acosta, Vikram Singh Bajaj, Jason Donald Thompson, Eric Peeters
  • Patent number: 9528980
    Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
    Type: Grant
    Filed: June 5, 2016
    Date of Patent: December 27, 2016
    Assignee: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey Bazarov
  • Patent number: 9474687
    Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 25, 2016
    Assignees: MONOSOL RX, LLC, MIDATECH LIMITED
    Inventors: Phillip Williams, Thomas Rademacher, Alexander Mark Schobel, Eric Dadey
  • Patent number: 9386938
    Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: July 12, 2016
    Assignee: Collagen Medical, LLC
    Inventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
  • Patent number: 9339539
    Abstract: The invention includes a magnetic nanoparticle molecular delivery vehicle to be used for transfection and delivery of therapeutic molecules across cell membranes and to specific sites in the body, using magnetic forces and ultrasound.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: May 17, 2016
    Assignee: Hidaca Limited
    Inventors: James Xing, Jie Chen
  • Patent number: 9289504
    Abstract: A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: March 22, 2016
    Assignee: The Regents of the University of California
    Inventors: Yunfeng Lu, Ming Yan, Juanjuan Du
  • Patent number: 9285449
    Abstract: Systems and methods for imaging and quantifying tissue magnetism with magnetic resonance imaging (MRI) are disclosed. According to an aspect, a method for MRI includes using an MRI system to acquire multiple image echoes of an object. The method also includes combining the image echoes. Further, the method includes generating an image of the object based on the combined image echoes for depicting a characteristic of the object.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: March 15, 2016
    Inventors: Chunlei Liu, Wei Li, Bing Wu
  • Patent number: 9150657
    Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: October 6, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
  • Patent number: 9075907
    Abstract: A medical diagnosis assistance system comprising an image data storage part, a substance distribution information acquiring part, a display part; and a control part. The image data storage part is configured to store image data of a brain function image. The substance distribution information acquiring part is configured to detect the signal from within the brain of a subject and to acquire, based on the detected signal, substance distribution information indicating the distribution of the quantity of specified endogenous substances in each part of the brain. The control part is configured to control the display part to display the brain function image and the image information based on said acquired substance distribution information.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: July 7, 2015
    Assignees: Kabushiki Kaisha Toshiba, Toshiba Medical Systems Corporation
    Inventor: Katsuhiko Fujimoto
  • Patent number: 9073990
    Abstract: An isolated pore-forming polypeptide is disclosed which comprises a naturally-occurring plugging module and a naturally-occurring pore domain, wherein at least one amino acid of the pore-forming polypeptide is mutated to generate a protease cleavage site, serving to at least partially remove the plugging module from the pore domain. The pore forming polypeptides may be inserted into an encapsulating particle and positioned such that it is capable of forming a pore through the lipid layer of the particle in a presence of the protease.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: July 7, 2015
    Assignee: Bar-llan University
    Inventors: Yoav Paas, Ilya Pittel, Uri Nir, Barak Ben-David
  • Patent number: 9074980
    Abstract: The present invention relates to a method for the toxicity assessment of nano-materials, and more specifically, it is relates to an objective, reproducible and accurate assessment method for the unbiased toxicity testings of nano-materials, which minimize artifacts of the conventional methods for the toxicity assessment of the nano-materials by considering the dose characteristics of the nano-material itself using Selective multi-Plane Illumination Microcopy (SPIM); and the response characteristics of the nano-material using the improved or novel cellular responses assessment methods for nano-materials (e.g., modified MTT assay using image cytometric analysis, normal-inverted exposure apparatus, and modified flow cytometry), and a system and an apparatus thereof.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: July 7, 2015
    Assignee: INDUSTRY-UNIVERSITY CORPORATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Tae-Hyun Yoon, Song-Hee Lee, Dong-Wook Kwon, Jong-Hoon Park, Hyun-Ju Yoo, Hyun-Woo Nho
  • Patent number: 9055919
    Abstract: A method includes concurrently modulating administration of at least two different contrast agents to a subject during an imaging procedure based on a modulation profile. The at least two different contrast agents exhibit different spectral characteristics. The method further includes performing a spectral decomposition of data indicative of the at least two different contrast agents, determining concentrations of the at least two different contrast agents based on the spectral reconstruction, and determining a perfusion parameter based on a ratio of the concentrations and the modulation profile.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: June 16, 2015
    Assignee: Koninklijke Philips N.V.
    Inventor: Roland Proksa
  • Publication number: 20150147278
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 28, 2015
    Applicants: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou